News

The investigational antibiotic, clovibactin, isolated from soil bacteria demonstrates unique mechanism against conserved site on drug-resistant bacteria.

COVID-19 reshaped the landscape of urinary tract infections (UTIs). Explore the prevalence of resistant pathogens, the impact on infection prevention, and the changes in positive pathogens.

After an all-day meeting, the FDA’s Antimicrobial Drugs Advisory Committee has voted to recommend nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.

The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.

New evidence suggests that oral transitional therapy may be a promising option for the treatment of infective endocarditis (IE). A retrospective cohort study reveals comparable clinical outcomes between oral and intravenous antibiotic regimens.

Cherokee Nation Health Services in Oklahoma found that 61% of patients diagnosed with HCV initiated care during the first five years of a program to eliminate HCV.

In this mini podcast, Kim Leuthner, PharmD, FIDSA, explores the challenges of choosing empirical therapy for complicated UTIs before culture results are available.

This study compares the mortality rates between Canada's public health care and the US private system, highlighting the complexities of pandemic response.

The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.

Unnecessary antibiotics for viral infections and incorrect prescriptions for bacterial infections have significant consequences, including increased adverse effects and healthcare expenditures.

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

Recognizing high-risk patients is crucial for effective management of UTIs, explains Kim Leuthner, PharmD, FIDSA.

The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.

COVID-19 and CMV coinfection caused the premature aging of immune systems, leading to a greater risk of cardiovascular disease at an earlier age, the study authors said.

With the CDC’s recent warning about it, this fungal infection is becoming more prevalent and is often multidrug resistant. Here are some infection prevention strategies to protect against its spread in health care facilities, where it is most common.

The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.

Following household COVID-19 transmissions for over 3 years, investigators found that 70.4% had a pediatric index case.

By repopulating the gut with healthy and diverse microbiota, Vowst aims to prevent further C diff recurrences and restore patients' quality of life.

A new study looked at the risk of hepatitis B and C as a result of exposure from such procedures.

Previously estimated 0.32% HBV prevalence in the US is closer to 0.55%, according to new modeling study that accounts for immigrant population.

Findings indicate that while the severity of health impairment decreases over time, 18% of unvaccinated participants still experience symptoms up to 2 years after infection.

From outbreaks to breakthroughs, these are the biggest infectious disease headlines from the past week.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

How does the diagnosis rate of mental health disorders after COVID-19 compare to that of other respiratory infections?

A new documentary looks at dealing with the condition long-term, and serves as a microcosm for how people suffer through chronic conditions and diseases, and may not get the help they need.

Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.

Neutralizing antibodies were initially lowest among Janssen vaccine recipients, but this all changed 6 months after vaccination.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

Sleep as a shield: A new study reveals that sleeping well before COVID-19 infection reduces the risk of post–COVID-19 condition (long COVID).